ABSTRACT
Forty-four patients suffering of hypoparathyroidism were receiving in the complex treatment vitamin D3. Blood calcium and phosphorus, parathyroid hormone, urinary excretion of calcium were determined. The primary clinical effect was manifest on the 3-7 day of treatment; the effect achieved its maximum in most patients by the 2-3 week and in some cases by the 3-6 months of treatment.
Subject(s)
Cholecalciferol/therapeutic use , Hypoparathyroidism/drug therapy , Adolescent , Adult , Child , Combined Modality Therapy , Drug Evaluation , Female , Humans , Hypoparathyroidism/blood , Hypoparathyroidism/etiology , Male , Middle Aged , Time FactorsSubject(s)
Acid-Base Equilibrium , Adrenal Gland Diseases/surgery , Lactates/blood , Pyruvates/blood , Adolescent , Adrenal Gland Diseases/metabolism , Adrenal Gland Neoplasms/surgery , Adult , Child , Child, Preschool , Cushing Syndrome/surgery , Humans , Intraoperative Period , Lactic Acid , Middle Aged , Pheochromocytoma/surgery , Postoperative Period , Pyruvic AcidABSTRACT
To inhibit corticotropic function of the pituitary and glucocorticoid function of the adrenal cortex in the treatment of 41 patients with Icenko-Cushing's disease, use was made of the steroidogenesis inhibitor chloditane and high doses of reserpine. The treatment data were compared to the effect of chloditane alone in 40 patients. Inclusion of reserpine into the complex of therapeutic measures led to an appreciable decrease in corticotropin secretion which increased again shortly after the drug discontinuation. The clinical results of the treatment were comparable to those attained with administration of chloditane alone. The majority of patients manifested recurrent disease 3 to 12 months after the treatment was discontinued. Therefore, administration of reserpine as an additional means in the treatment was discontinued. Therefore, administration of reserpine as an additional means in the treatment of Icenko-Cushing's disease by chloditane with a view of a steady inhibition of corticotropic function of the pituitary and the prophylaxis of recurrencies is not desirable. High doses of reserpine may be recommended at the initial stages of the disease treatment in the presence of an extremely high level of blood plasma corticotropin.
Subject(s)
17-Hydroxycorticosteroids/antagonists & inhibitors , Adrenocorticotropic Hormone/antagonists & inhibitors , Cushing Syndrome/drug therapy , Mitotane/administration & dosage , Reserpine/administration & dosage , Drug Therapy, Combination , Follow-Up Studies , HumansABSTRACT
The results are presented of the combined drug treatment of 39 patients with Icenko-Cushing's disease, using steroidogenesis inhibitor chloditane (o.p-DDD) and corticotropin secretion blocker peritol (cyproheptadine). The control group of 40 patients, suffered from the above disease of the same severity, was treated with alone chloditane. In the control group the inhibition of the adrenocortical glucocorticoid activity by chloditane was accompanied by twofold increase in the blood plasma corticotropin level. The relapse was noted in 24 of 40 patients after 5 to 6 months. The inhibition of glucocorticoid activity did not induce corticotropin secretion activation in patients, treated with chloditane and peritol. At the delayed terms of the treatment course the basal level of plasmatic corticotropin continued to lower and averaged the subnormal values. Relapses of the disease were seen in only 8 of 39 patients. The combined chloditane-perikol treatment of Icenko-Cushing's disease is likely to be perspective.
